1. Home
  2. SKYE vs ACNB Comparison

SKYE vs ACNB Comparison

Compare SKYE & ACNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • ACNB
  • Stock Information
  • Founded
  • SKYE 2012
  • ACNB 1857
  • Country
  • SKYE United States
  • ACNB United States
  • Employees
  • SKYE N/A
  • ACNB 413
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • ACNB Major Banks
  • Sector
  • SKYE Health Care
  • ACNB Finance
  • Exchange
  • SKYE Nasdaq
  • ACNB Nasdaq
  • Market Cap
  • SKYE 294.2M
  • ACNB 318.6M
  • IPO Year
  • SKYE N/A
  • ACNB N/A
  • Fundamental
  • Price
  • SKYE $6.44
  • ACNB $37.31
  • Analyst Decision
  • SKYE Strong Buy
  • ACNB Hold
  • Analyst Count
  • SKYE 4
  • ACNB 1
  • Target Price
  • SKYE $19.25
  • ACNB $37.00
  • AVG Volume (30 Days)
  • SKYE 414.1K
  • ACNB 17.0K
  • Earning Date
  • SKYE 01-01-0001
  • ACNB 07-25-2024
  • Dividend Yield
  • SKYE N/A
  • ACNB 3.43%
  • EPS Growth
  • SKYE N/A
  • ACNB N/A
  • EPS
  • SKYE N/A
  • ACNB 3.46
  • Revenue
  • SKYE N/A
  • ACNB $104,406,000.00
  • Revenue This Year
  • SKYE N/A
  • ACNB $3.30
  • Revenue Next Year
  • SKYE N/A
  • ACNB $3.50
  • P/E Ratio
  • SKYE N/A
  • ACNB $10.78
  • Revenue Growth
  • SKYE N/A
  • ACNB N/A
  • 52 Week Low
  • SKYE $1.44
  • ACNB $30.24
  • 52 Week High
  • SKYE $19.41
  • ACNB $48.55
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 36.20
  • ACNB 66.10
  • Support Level
  • SKYE $5.48
  • ACNB $32.51
  • Resistance Level
  • SKYE $6.93
  • ACNB $36.50
  • Average True Range (ATR)
  • SKYE 1.03
  • ACNB 1.21
  • MACD
  • SKYE -0.03
  • ACNB 0.33
  • Stochastic Oscillator
  • SKYE 37.30
  • ACNB 87.56

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About ACNB ACNB Corporation

ACNB Corp provides banking, insurance, and financial services to businesses and consumers, through its wholly-owned subsidiaries, ACNB Bank and ACNB Insurance Services, Inc. The corporation has two reporting segments; the Bank which generates the majority of the revenue provides banking and wealth management services, including trust and retail brokerage, and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.

Share on Social Networks: